-
公开(公告)号：US20230091510A1
公开(公告)日：2023-03-23
申请号：US17612280
申请日：2020-05-19
Applicant: Novartis AG
Inventor： Zhuoliang CHEN , Katsumasa NAKAJIMA , Matthew T. BURGER , Joseph Anthony D'ALESSIO , Eric MCNEILL , Mark G, PALMERO , Bing YU , Qiang ZHANG
Abstract: Provided herein are linkers, linker-drug groups and anti-body-drug conjugates comprising hydrophilic groups.
-
公开(公告)号：US20180362542A1
公开(公告)日：2018-12-20
申请号：US16062680
申请日：2016-12-14
Applicant: Novartis AG
Inventor： Robert John AVERSA , Matthew T. BURGER , Michael Patrick DILLON , Thomas A. DINEEN, Jr. , Rajesh KARKI , Savrithi RAMURTHY , Vivek RAUNIYAR , Richard ROBINSON , Patrick James SARVER
IPC: C07D498/04 , C07D491/044 , C07D487/04 , A61P35/00
CPC classification number: C07D498/04 , A61P35/00 , C07D487/04 , C07D491/04 , C07D491/044
Abstract: The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.
-
Patent Agency Ranking
公开(公告)号：US20170260200A1
公开(公告)日：2017-09-14
申请号：US15510613
申请日：2015-09-11
Applicant: NOVARTIS AG
Inventor： Paul Andrew BARSANTI , Matthew T. BURGER , Yan LOU , Gisele A. NISHIGUCHI , Valery Rostislavovich POLYAKOV , Savithri RAMURTHY , Sharadha SUBRAMANIAN , Benjamin R. TAFT , Huw Rowland TANNER , Lifeng WAN
IPC: C07D498/08 , A61K31/4418 , A61K31/444 , C07D401/14 , C07D213/74 , C07D405/12 , A61K31/541 , A61K31/5377 , C07D401/04 , C07D405/14 , A61K31/496 , C07D413/14 , C07D451/02 , A61K31/501 , C07D213/85
CPC classification number: C07D498/08 , A61K31/4418 , A61K31/444 , A61K31/496 , A61K31/501 , A61K31/5377 , A61K31/541 , C07D213/74 , C07D213/85 , C07D401/04 , C07D401/10 , C07D401/14 , C07D405/12 , C07D405/14 , C07D407/14 , C07D411/14 , C07D413/12 , C07D413/14 , C07D451/02
Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US20210228731A1
公开(公告)日：2021-07-29
申请号：US17253584
申请日：2019-06-19
Applicant: NOVARTIS AG
Inventor： Anthony Edward BOITANO , Matthew T. BURGER , Susan E. CELLITTI , Michael Paul COOKE , Catrin FINNER , Bernhard Hubert GEIERSTANGER , Si-Tuen LEE-HOEFLICH , HongNgoc Thi PHAM , Siew Ho SCHLEYER , Kathrin TISSOT , Tetsuo UNO , Yongqin WAN , Ben WEN , Qiang ZHANG
Abstract: The present invention provides antibody drug conjugates, wherein an antibody or antibody fragment that specifically binds to human cKIT is linked to a drug moiety, optionally through a linker. The present invention further provides pharmaceutical compositions comprising the antibody drug conjugates; and methods of making and using such pharmaceutical compositions for ablating hematopoietic stem cells in a patient in need thereof.
-
公开(公告)号：US20190175606A1
公开(公告)日：2019-06-13
申请号：US16274165
申请日：2019-02-12
Applicant: NOVARTIS AG
Inventor： Robert John AVERSA , Paul Andrew BARSANTI , Matthew T. BURGER , Michael Patrick DILLON , Alan DIPESA , Cheng HU , Yan LOU , Gisele A. NISHIGUCHI , Yue PAN , Valery Rostislavovich POLYAKOV , Savithri RAMURTHY , Alice C. RICO , Lina Quattrocchio SETTI , Aaron SMITH , Sharadha SUBRAMANIAN , Benjamin R. TAFT , Huw Roland TANNER , Lifeng WAN , Naeem YUSUFF
IPC: A61K31/5377 , C07D493/10 , C07D403/12 , C07D413/14 , C07D413/12 , C07D403/04 , C07D401/12 , C07D277/42 , C07D239/48 , C07D239/47 , C07D239/42 , C07D237/20 , C07D213/74 , A61K45/06 , A61K31/541 , C07D413/04 , C07D491/08 , C07B59/00 , C07D417/12 , C07D237/24 , C07D491/04 , A61K31/444 , A61K31/501 , C07D513/04 , C07D491/048 , A61K31/5375 , C07D213/81 , C07D213/82 , C07D213/84 , C07D237/22 , C07D409/14 , C07D498/08 , C07D495/04 , C07D493/04 , C07D491/107 , C07D263/58 , C07D487/04 , C07D471/04 , C07D241/20 , C07D405/12 , C07D405/04 , C07D401/04 , C07D233/88 , C07D213/75 , C07D405/14 , C07D401/14
Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US20180170917A1
公开(公告)日：2018-06-21
申请号：US15510609
申请日：2015-09-11
Applicant: NOVARTIS AG
Inventor： Robert John AVERSA , Matthew T. BURGER , Michael Patrick DILLON , Thomas A. DINEEN, Jr. , Yan LOU , Gisele A. NISHIGUCHI , Savithri RAMURTHY , Alice C. RICO , Vivek RAUNIYAR , Martin SENDZIK , Sharadha SUBRAMANIAN , Lina Quattrocchio SETTI , Benjamin R. TAFT , Huw Rowland TANNER , Lifeng WAN
IPC: C07D405/14 , C07D405/12 , C07D305/06 , C07D413/14 , A61P35/00
CPC classification number: C07D405/14 , A61P35/00 , C07D305/06 , C07D405/12 , C07D413/14
Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
公开(公告)号：US20170260207A1
公开(公告)日：2017-09-14
申请号：US15601423
申请日：2017-05-22
Applicant: NOVARTIS AG
Inventor： Robert John AVERSA , Paul Andrew BARSANTI , Matthew T. BURGER , Michael Patrick DILLON , Alan DIPESA , Cheng HU , Yan LOU , Gisele A. NISHIGUCHI , Yue PAN , Valery Rostislavovich POLYAKOV , Savithri RAMURTHY , Alice C. RICO , Lina Quattrocchio SETTI , Aaron SMITH , Sharadha SUBRAMANIAN , Benjamin R. TAFT , Huw Roland TANNER , Lifeng WAN , Naeem YUSUFF
IPC: C07D513/04 , A61K31/5377 , C07D213/74 , C07D237/22 , C07D213/84 , C07D213/81 , C07D213/75 , C07D401/14 , C07D405/14 , C07D413/12 , C07D413/14 , C07D491/08 , A61K31/444 , C07D241/20 , C07D401/04 , C07D237/24 , C07D237/20 , A61K31/501 , C07D239/48 , C07D403/04 , C07D487/04 , C07D471/04 , C07D263/58 , C07D495/04 , C07D491/04 , C07D409/14 , C07D413/04 , C07B59/00 , C07D401/12
CPC classification number: A61K31/5377 , A61K31/444 , A61K31/501 , A61K31/5375 , A61K31/541 , A61K45/06 , C07B59/002 , C07B2200/05 , C07D213/74 , C07D213/75 , C07D213/81 , C07D213/82 , C07D213/84 , C07D233/88 , C07D237/20 , C07D237/22 , C07D237/24 , C07D239/42 , C07D239/47 , C07D239/48 , C07D241/20 , C07D263/58 , C07D277/42 , C07D401/04 , C07D401/12 , C07D401/14 , C07D403/04 , C07D403/12 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/14 , C07D413/04 , C07D413/12 , C07D413/14 , C07D417/12 , C07D471/04 , C07D487/04 , C07D491/04 , C07D491/048 , C07D491/08 , C07D491/107 , C07D493/04 , C07D493/10 , C07D495/04 , C07D498/08 , C07D513/04
Abstract: The present invention provides compounds of Formula (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.
-
-
-
-
-
-
Search Results
7
records
(took 0.031 seconds)
